Strides Pharma partners with Kenox to expand nasal spray portfolio in US market

Drug firm Strides Pharma Science Ltd on Monday (September 8) announced that its wholly-owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has entered into a strategic product development partnership with Kenox Pharmaceuticals Inc.

The collaboration aims to enhance Strides’ pipeline of nasal spray products for the US market across a range of therapeutic areas.

Kenox, a rapidly-growing contract development and manufacturing organisation specialising in orally inhaled and nasal drug products (OINDPs), will provide formulation and development expertise to support Strides in the creation and regulatory filing of multiple nasal spray products.

While specific product details are yet to be disclosed, the partnership is designed to accelerate the availability of affordable, high-quality medicines for patients in the US.

Also Read: Strides Pharma outperforms guidance of 12–15%, aided by strong US business performance in Q4

Aditya Kumar, Executive Director Business Development, Strides Pharma Science, said, "Nasal sprays have consistently been highlighted as a key focus area for Strides, and this collaboration further builds on the solid progress we have already made in this domain."

"Kenox’s formulation and development strengths perfectly complement our manufacturing and go-to-market strengths, allowing us to accelerate our range of nasal spray offerings in the US market," he added.

Dr Sitaram Velaga, Founder, President and CEO of Kenox Pharmaceuticals Inc, said, "Our strategic partnership with Strides is a significant milestone for Kenox. This collaboration validates our expertise in the OINDP space and will allow us to leverage our capabilities to bring important drug products to global patients at an affordable price."

Also Read: Strides Pharma confident of US growth, sticks to $400 million FY28 sales goal

Shares of Strides Pharma Science Ltd ended at ₹879, down by ₹11.35 or 1.27%, on the BSE today (September 8).